We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, whi...
We are a clinical-stage biopharmaceutical company focused on the development of Aramchol™, liver-targeted stearoyl-coenzyme A desaturase‑1 (“SCD1ˮ) modulator, a first in class, novel, once-daily, oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
We believe that our product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that constitutes a large unmet medical need.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.